CN101801375B - 胰岛素增敏剂和治疗方法 - Google Patents

胰岛素增敏剂和治疗方法 Download PDF

Info

Publication number
CN101801375B
CN101801375B CN200880005674.3A CN200880005674A CN101801375B CN 101801375 B CN101801375 B CN 101801375B CN 200880005674 A CN200880005674 A CN 200880005674A CN 101801375 B CN101801375 B CN 101801375B
Authority
CN
China
Prior art keywords
alkyl
metformin
treatment
methazolamide
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880005674.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801375A (zh
Inventor
G·R·克里尔
K·R·瓦尔德
J·A·坎贝尔
J-C·莫雷罗-纳瓦加斯
N·康斯坦托普罗斯
G·Y·克里普纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verva Pharmaceuticals Ltd
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902013A external-priority patent/AU2007902013A0/en
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of CN101801375A publication Critical patent/CN101801375A/zh
Application granted granted Critical
Publication of CN101801375B publication Critical patent/CN101801375B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200880005674.3A 2007-01-25 2008-01-25 胰岛素增敏剂和治疗方法 Expired - Fee Related CN101801375B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US89776907P 2007-01-25 2007-01-25
US60/897,769 2007-01-25
AU2007902013 2007-04-17
AU2007902013A AU2007902013A0 (en) 2007-04-17 Inhibitory compounds
US98433507P 2007-10-31 2007-10-31
US60/984,335 2007-10-31
US737607P 2007-12-11 2007-12-11
US61/007,376 2007-12-11
PCT/AU2008/000089 WO2008089521A1 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Publications (2)

Publication Number Publication Date
CN101801375A CN101801375A (zh) 2010-08-11
CN101801375B true CN101801375B (zh) 2014-01-01

Family

ID=39644028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880005674.3A Expired - Fee Related CN101801375B (zh) 2007-01-25 2008-01-25 胰岛素增敏剂和治疗方法

Country Status (12)

Country Link
US (3) US8455432B2 (enExample)
EP (1) EP2106260B8 (enExample)
JP (1) JP5301465B2 (enExample)
CN (1) CN101801375B (enExample)
AU (1) AU2008209320B2 (enExample)
CA (1) CA2676051C (enExample)
ES (1) ES2660170T3 (enExample)
NO (1) NO2106260T3 (enExample)
NZ (1) NZ579229A (enExample)
PL (1) PL2106260T3 (enExample)
PT (1) PT2106260T (enExample)
WO (1) WO2008089521A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008209320B2 (en) 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
US20200155558A1 (en) * 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2854806A4 (en) 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION
SG10201705388XA (en) * 2012-05-24 2017-07-28 Verva Pharmaceuticals Ltd A Method Of Improving Liver Function
AU2013202988B2 (en) * 2012-06-29 2016-04-21 NAIA Metabolic, Inc. Method of improving liver function
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2994701A (en) 1961-08-01 Z-sulfamyr
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
US2835702A (en) * 1956-05-02 1958-05-20 Merck & Co Inc Benzene 1, 3 disulfonamides possessing diuretic properties
US2978457A (en) 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) * 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US3668248A (en) * 1964-09-30 1972-06-06 Lilly Co Eli 5-chloro-2,4-bis(sulfamoyl)fluorobenzene and 5-chloro-2,4-bis(chlorosulfonyl)fluorobenzene
FR2468366A1 (fr) 1979-10-31 1981-05-08 Stoclet Alain Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide
ATE35265T1 (de) 1982-05-28 1988-07-15 Ciba Geigy Ag Neue sulfonyl(thio)harnstoffe, verfahren zu deren herstellung und deren verwendung als herbizide und/oder wachstumsregulatoren.
IT1224860B (it) 1988-07-29 1990-10-24 Istituto Chimico Internazional Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
GB2223166B (en) 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US4990523A (en) * 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5225424A (en) 1992-10-21 1993-07-06 University Of Iowa Research Foundation Methazolamide-derived carbonic anhydrase inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK0869785T3 (da) 1995-11-17 2002-12-16 Upjohn Co 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
DK1309324T3 (da) * 2000-07-07 2006-06-12 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE60110087T2 (de) 2000-08-11 2005-09-29 Einar Stefansson Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
ATE286078T1 (de) 2000-12-22 2005-01-15 Dow Global Technologies Inc Propylencopolymerschäume
ATE341343T1 (de) * 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
MXPA05009933A (es) 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1680131A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDOLE-O-GLUCOSIDES
US7705052B2 (en) 2003-09-12 2010-04-27 Merck Serono Sa Sulfonamide derivatives for the treatment of diabetes
US20050197376A1 (en) 2004-03-02 2005-09-08 Fujisawa Pharmaceutical Co. Ltd. Concomitant drugs
CN1997370B (zh) * 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
WO2007030375A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
US7670794B2 (en) * 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
JP2009515928A (ja) 2005-11-14 2009-04-16 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カルボニックアンヒドラーゼの阻害剤としてのｎ−スルファモイル−ｎ’−ベンゾピランピペリジン
AR057570A1 (es) * 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
ZA200804077B (en) 2005-12-09 2009-10-28 Solvay Pharmaceutical Gmbh Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007114948A2 (en) 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
AU2008209320B2 (en) 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
JPWO2011002011A1 (ja) 2009-07-01 2012-12-13 キッセイ薬品工業株式会社 Ｓｇｌｔ１阻害薬とｄｐｐ−ｉｖ阻害薬を組み合わせてなる医薬
DK3459558T3 (da) 2010-06-25 2020-11-02 Univ Aston Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
EP2854806A4 (en) 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION
SG10201705388XA (en) 2012-05-24 2017-07-28 Verva Pharmaceuticals Ltd A Method Of Improving Liver Function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation

Also Published As

Publication number Publication date
WO2008089521A1 (en) 2008-07-31
US9452148B2 (en) 2016-09-27
PL2106260T3 (pl) 2018-06-29
EP2106260B1 (en) 2017-12-06
US8455432B2 (en) 2013-06-04
AU2008209320B2 (en) 2013-05-30
ES2660170T3 (es) 2018-03-21
US20170079960A1 (en) 2017-03-23
CA2676051A1 (en) 2008-07-31
NO2106260T3 (enExample) 2018-05-05
US20140011848A1 (en) 2014-01-09
US10172837B2 (en) 2019-01-08
CN101801375A (zh) 2010-08-11
EP2106260A4 (en) 2010-05-26
CA2676051C (en) 2017-06-06
EP2106260B8 (en) 2018-04-04
AU2008209320A1 (en) 2008-07-31
NZ579229A (en) 2011-07-29
EP2106260A1 (en) 2009-10-07
PT2106260T (pt) 2018-03-05
US20110003740A1 (en) 2011-01-06
JP2010516711A (ja) 2010-05-20
JP5301465B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
US10172837B2 (en) Insulin sensitisers and methods of treatment
JP7542518B2 (ja) ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
CZ297386B6 (cs) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridin-1-oxid-3-karboximidoylchlorid, N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridin-1-oxid-3-karboximidoylchlorid pro pouzití pri lécbe rezistence vuci inzulínua farmaceutický prípravek ho obsahující
US20120289476A1 (en) Methods for treating methylmalonic acidemia
US10245255B2 (en) Compositions and methods for the treatment of obesity and related disorders
JP2008504295A (ja) 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物
HUE029479T2 (en) Preparations and methods for treating diabetes and neuropsychological disorder
HK1132198A (en) Insulin sensitisers and methods of treatment
HK1132198B (en) Insulin sensitisers and methods of treatment
MX2014014316A (es) Método de reducción de peso.
IL303006A (en) Use of pyridofidine and analogues for the treatment of Rett syndrome
US10835532B2 (en) Muscarinic agonists as cognitive enhancers
JP4227121B2 (ja) 神経因性疼痛治療剤
US10287290B2 (en) Compositions useful in treating brain-related diseases or disorders and methods using same
HK40123243A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
HK40086209B (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
HK40086209A (zh) 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法
HK40108227A (zh) 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
WO2006085686A1 (ja) 神経因性疼痛治療剤
WO2003047625A1 (en) Neural transmission promoters
WO2007026928A1 (ja) 神経因性疼痛治療剤
JPWO2003013522A1 (ja) コリン作動性神経障害予防・治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180511

Address after: Grand Cayman, Cayman Islands

Patentee after: Verva Pharmaceuticals Ltd.

Address before: Vitoria Australia

Patentee before: Verva Pharmaceuticals Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140101

Termination date: 20220125

CF01 Termination of patent right due to non-payment of annual fee